The claim
Prescription drug prices experienced the largest decline in over 60 years under President Trump.View original claim · Donald Trump
Original wording
President Trump delivered the largest drop in prescription drug prices in over 60 years.
The finding
Prescription drug prices experienced their steepest year-over-year decline since 1963 (a drop of over 60 years) during President Trump's administration. While the administration attributes this decline to its recent drug pricing deals and the TrumpRx platform, drug pricing experts note the drop is likely driven by a complex mix of factors, including market pressures on GLP-1 drugs, an increase in generics, and Medicare negotiation policies enacted under the prior administration.
Context
A White House article on whitehouse.gov said "President Trump delivered the largest drop in prescription drug prices in over 60 years," crediting the administration's Most Favored Nation drug deals and its TrumpRx platform.
Evidence
FactCheck.org reported that Bureau of Labor Statistics consumer price data showed prescription drug prices down 3.1% over the past year, the largest one-year decrease since 1963. The Washington Post reported the same record year-over-year drop for July. Experts quoted by FactCheck.org, including KFF's Cynthia Cox, pointed to falling GLP-1 prices and more generics, along with a Biden-era policy letting Medicare negotiate drug prices. The Post's experts likewise cited generics and discount GLP-1 drugs. Of the administration's deals, Brookings' Richard Frank told FactCheck.org it is "really unlikely that they are the major drivers here." AP News also reported on the question.
Analysis
The record decline and its timing hold up. The credit does not. The experts cited say the administration's chosen explanations probably played a small part in a drop with several causes.
Conclusion
Credible. Drug prices did fall by the most since 1963 under Trump, but the evidence points to several drivers beyond his deals and TrumpRx.
Sources
Also reported by
These pages were listed in the check but were not read as evidence for this article.
Methodology note
Selected from the office-based roster: Donald Trump (President of the United States), in "Fact Sheet: President Donald J. Trump Protects the Executive’s Privileges and Enhances Efficiencies in Federal Contracting" (whitehouse.gov, 2026-11-21). Re-filed as an economics claim on 2026-11-21 (board ruling: drug prices and funding are business, not medicine; no primary medical source required).

